&#35; Andrew Dudum

🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims

Hims House

LS 25

TOP 10%

1 जुलाई 2026

Thanks to our partner:Superpower - https://superpower.com In episode 72 of Hims House, Jonathan Stern interviews David Wells, Hims board member and former Netflix CFO, about his recent $1.2 million open-market purchase of Hims shares. Wells explains why he believes the company is at an inflection …

00:51:23

Healthcare is Broken—This Company Wants to Fix It

Prof G Markets

LS 58

TOP 0.5%

5 जुलाई 2026

Ed Elson sits down with Andrew Dudum, co-founder and CEO of Hims & Hers, to discuss why the company went public so early, how it made GLP-1s more affordable, and whether healthcare regulation has gone too far. They also explore why Hims & Hers chose to disrupt the system instead of working within i…

01:00:31

Hims & Hers Q2 2026: Growth Up, Margins Down

Quarters

11 अगस्त 2026 · अनुलिपि

Send us Fan Mail Hims & Hers accelerated revenue growth while gross margin fell twelve percentage points. Management calls the quarter proof that the model can scale. The income statement asks for patience.In this episode of Quarters, Andrew Dudum argues that Hims can expand access to care and rema…

00:04:12

Hims Preps Peptides, Abbott Syncs with Google, Amazon Targets Pharma

Fitt Insider

LS 37

TOP 2.5%

12 अगस्त 2026

August 12, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Hims CEO Andrew Dudum says the company plans to offer approved peptides by year-end, leveraging 19% subscriber growth to 2.9 million as a distribution channel Abbott's Lingo glucose data i…

00:02:24

Hims Preps Peptides, Abbott Syncs with Google, Amazon Targets Pharma

Fitt Insider

LS 42

TOP 1.5%

12 अगस्त 2026

00:02:24

AI “Genies” & Hims & Hers CEO Andrew Dudum 8/18/26

Squawk Pod

LS 52

TOP 0.5%

18 अगस्त 2026

In an exclusive, rare interview, CEO and co-founder of Hims & Hers Andrew Dudum sits down with Andrew Ross Sorkin. Dudum maps out his vision for an AI-enabled American healthcare system, comments on the FTC’s lawsuit, and reflects on his company’s impact on GLP1 access and affordability. CNBC’s Ale…

00:54:02

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

On The Pen GLP-1 News

LS 49

TOP 0.5%

18 अगस्त 2026

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America. But getting there may depend on something most patients have never heard of: the global peptide manufactu…

00:45:01

The Grand Roundup: Q2 earnings special — AI ROI finally shows up, managed care's comeback, Molina's ACA spiral, Hims' Bluetooth pill box pitch, and more

Health Tech Nerds Radio

24 अगस्त 2026

Kevin and Martin are out this week, so TGR is running our Q2 earnings wrap-up with HTN's Sean Leimbach, covering the quarter across the HTN Research coverage universe. First up: AI. Centene's Sarah London gave what Kevin calls “the quote of earnings season” on the risk of spending big with no retur…

00:59:07